A Goldhirsch
Director, Scientific and Clinical Evaluation Board
IEO European Institute of Oncology
Italy
Biography
Aron Goldhirsch Department of Medicine European Institute of Oncology Via Ripamonti 435, 20141 Milan, ItalyMedicalResearch.com Interview with: Prof Aron Goldhirsch Department of Medicine Prof. Goldhirsch: Two years of adjuvant trastuzumab after standard chemotherapy is not more effective than is 1 year of treatment with the drug for patients with HER2-positive early breast cancer.
Research Interest
Oncology, Breat Cancers, Chemotherapy
